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1 Crossover randomized controlled trial 
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2 Electrodiagnostic test 
3 Nerve conduction study 
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Eye.R.La(ms) 87/13±79/114 41/14±37/115 06/4±58/0Ns 
Eye.R.Am (M)80/6±01/1172/5±19/1079/1±82/0011/0
Eye.L.La (ms) 36/13±38/116 17/15±84/117 62/2±46/1002/0
Eye.L.Am (M)10/8±60/1144/6±61/1010/2±99/0009/0
Medianus.Dis. R.M.La (ms) 75/0±08/465/0±29/427/0±21/0001/0<
Medianus.Dis.R.M.Am (mv) 06/6±06/1483/5±86/1374/0±20/0Ns 
Proximal. M.NCV(m/s) 49/8±26/4566/7±36/4556/3±11/0Ns 
Suralis. Dis.S.R. La(ms) 83/0±68/380/0±75/322/0±07/0Ns 
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Eye.R.La(ms) 26/13±43/119 07/13±38/116 49/5±04/3002/0
Eye.R.Am (M)96/5±44/942/7±75/1007/2±31/1001/0
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1 Mitz 
2 End stage renal disease 
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Eye.R.La(ms) 36/15±56/122 77/15±85/119 44/7±71/2Ns 
Eye.R.Am (M)48/7±90/1009/8±65/1126/2±74/0Ns 




Proximal. M.NCV(m/s) 45/8±53/4858/7±55/5150/8±01/3Ns 
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Eye.R.Am (M)86/6±51/1021/5±33/892/3±19/2005/0
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Background and Objectives: Neuropathy is a common complication in hemodialysis patients. 
The purpose of this investigation is examination of the effect of zinc supplementation on 
nerve conduction velocity in chronic hemodialysis patients. 
Methods: In this clinical trial 65 chronic hemodialysis patients were studied in two groups: 
Group one (35 patients) received 100 mg placebo (corn starch) and group two (30 patients) 
received 100 mg elemental zinc (as zinc sulfate) daily for 2 months. The placebo and 
supplement discontinued in the next 2 months. Then, the study continued for two other 
months in the cross-over form; group one received 100 mg zinc and group two received 100 
mg placebo daily for 2 months. The function of central and peripheral nerves were evaluated 
at the 0th, 60th, 120th, 180th days by nerve conduction velocity of electrodiagnostic test. 
Results: The function of nerves didn’t change significantly or some parameters markedly 
decreased in placebo period in both groups. Significant increase was found in the function of 
nerves during zinc supplementation period in both groups.  
Conclusion: These data indicate that zinc supplementation improve neuron function in 
patients undergoing hemodialysis    
Key Words: Zinc; Hemodialysis; Neuropathy; Nerve conduction velocity 
 
